Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

REVERSAL OF BRAIN METABOLIC ABNORMALITIES FOLLOWING TREATMENT OF AIDS DEMENTIA COMPLEX WITH 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE (AZT, ZIDOVUDINE) - A PET-FDG STUDY JOURNAL OF NUCLEAR MEDICINE Brunetti, A., Berg, G., DICHIRO, G., Cohen, R. M., Yarchoan, R., Pizzo, P. A., Broder, S., Eddy, J., Fulham, M. J., Finn, R. D., Larson, S. M. 1989; 30 (5): 581-590

Abstract

Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine), and later in the course of therapy. In two patients, baseline, large focal cortical abnormalities of glucose utilization were reversed during the course of therapy. In the other two patients, the initial PET study did not reveal pronounced focal alterations, while the post-treatment scans showed markedly increased cortical glucose metabolism. The improved cortical glucose utilization was accompanied in all patients by immunologic and neurologic improvement. PET-FDG studies can detect cortical metabolic abnormalities associated with AIDS dementia complex, and may be used to monitor the metabolic improvement in response to AZT treatment.

View details for Web of Science ID A1989U651100002

View details for PubMedID 2785582